A5077232908- Sarcoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- Vascular Tumors and Angiosarcomas
- Lymphoma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Treatments and Mutations
- Neuroblastoma Research and Treatments
- Cardiac tumors and thrombi
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Helicobacter pylori-related gastroenterology studies
- Colorectal and Anal Carcinomas
- Testicular diseases and treatments
- Gastric Cancer Management and Outcomes
- Soft tissue tumor case studies
- Lung Cancer Research Studies
- Animal Nutrition and Physiology
- Virus-based gene therapy research
- Cancer Research and Treatments
- Ovarian cancer diagnosis and treatment
- Statistical Methods in Clinical Trials
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Diagnosis and Treatment
University of Michigan
2013-2023
Michigan Medicine
2007-2023
University Hospital Southampton NHS Foundation Trust
2021-2022
The Recovery Center
2022
Scotland's Rural College
2016-2022
Sarcoma Alliance for Research through Collaboration
2011-2020
Cleveland Clinic
1991-2016
The University of Texas MD Anderson Cancer Center
1976-2016
Columbia University Irving Medical Center
2016
Mallinckrodt (United States)
2016
<h3>Context</h3>Secondary analyses of 2 randomized controlled trials and supportive epidemiologic preclinical data indicated the potential selenium vitamin E for preventing prostate cancer.<h3>Objective</h3>To determine whether selenium, E, or both could prevent cancer other diseases with little no toxicity in relatively healthy men.<h3>Design, Setting, Participants</h3>A randomized, placebo-controlled trial (Selenium Vitamin Cancer Prevention Trial [SELECT]) 35 533 men from 427...
<h3>Context</h3>The initial report of the Selenium and Vitamin E Cancer Prevention Trial (SELECT) found no reduction in risk prostate cancer with either selenium or vitamin supplements but a statistically nonsignificant increase E. Longer follow-up more events provide further insight into relationship cancer.<h3>Objective</h3>To determine long-term effect on relatively healthy men.<h3>Design, Setting, Participants</h3>A total 35 533 men from 427 study sites United States, Canada, Puerto Rico...
To assess potential differences in progression-free or overall survival when imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors (GIST) at a standard dose (400 mg daily) versus high twice daily).Patients metastatic surgically unresectable GIST were eligible for this phase III open-label clinical trial. At registration, randomly assigned either high-dose imatinib, close interval follow-up. If objective progression occurred by Response Evaluation...
Purpose Gemcitabine as a single agent and the combination of gemcitabine docetaxel have activity in patients with metastatic soft tissue sarcoma. To determine if addition to improved clinical outcome sarcomas, we compared fixed dose rate infusion versus lower docetaxel. Patients Methods In this open-label phase II trial, primary end point was tumor response, defined complete or partial response stable disease lasting at least 24 weeks. A Bayesian adaptive randomization procedure used produce...
To evaluate the safety and efficacy of trabectedin in a phase II, open-label, multicenter, randomized study adult patients with unresectable/metastatic liposarcoma or leiomyosarcoma after failure prior conventional chemotherapy including anthracyclines ifosfamide.Patients were randomly assigned to one two regimens (via central venous access): 1.5 mg/m(2) 24-hour intravenous infusion once every 3 weeks (q3 24-hour) versus 0.58 3-hour IV week for 4-week cycle (qwk 3-hour). Time progression...
In a randomized series of 70 patients with colo rectal adenocarcinoma, comparison systemic 5-fluorouracil chemotherapy administered as continuous 120-hours infusion vs. intravenous bolus injection daily for 5 days demonstrated superiority prolonged infusion. The most striking advantage 5-FU was the absence myelotoxicity. Fifteen 34 treated and 8 36 by developed objective tumor responses. difference in response rate at least part is explainable unequal distribution different characteristics...
Four hundred and seventy-two patients with disseminated neoplasia were treated two or more doses of adriamycin. The initial dose for "good risk" was 75 mg/m2 every 3 weeks, "poor 60 weeks. Objective remissions seen in 118/472 patients, best results noted lymphomas (21/48), sarcomas (21/64), carcinoma the breast (16/50). Eighty-nine per cent occurred within three courses. Hematopoietic toxic effects 73% patients; nausea, vomiting, and/or stomatitis observed 43%. Changes electrocardiograms...
One hundred and twenty-two patients with clinically advanced, histologically confirmed, cutaneous malignant melanoma, seen at Wayne State University over a 12 year period were reviewed. The incidence of central nervous system metastases (CNS) diagnosed was 46% autopsy 75%. Meningeal involvement suspected in 10.6% found 52%. Motor dysfunction, mental confusion, cranial nerve disturbance, as well headache, the most common manifestations. EEG to be extremely sensitive predicting confirming CNS...
Because patients treated with 60–90 mg/m2 every three to four weeks reach cardiotoxic doses of 550 within 36 weeks, prolonged treatment Adriamycin is limited. The purpose this study was determine whether lower could be given over longer periods without loss efficacy. Good risk 75, 60, or 45 had remission rates 25, 27, and 19%; poor 50 25 16 12% respectively. Although a dose response identified, there were no statistically significant differences in rates, durations remission, toxicities the...
The type 1 insulin-like growth factor receptor (IGF-1R) has been implicated in the pathogenesis of Ewing sarcoma family tumors (ESFT). We conducted a multicenter phase II study fully human IGF-1R monoclonal antibody R1507 patients with recurrent or refractory ESFT.Patients ≥ 2 years age ESFT received at doses 9 mg/kg intravenously one week 27 every three weeks. Response was measured by using WHO criteria. Tumor imaging performed 6 weeks for 24 and then 12 weeks.From December 2007 through...
Purpose Ridaforolimus is an inhibitor of mammalian target rapamycin, integral component the phosphatidyl 3-kinase/AKT signaling pathway, with early evidence activity in sarcomas. This multicenter, open-label, single-arm, phase II trial was conducted to assess antitumor ridaforolimus patients distinct subtypes advanced Patients and Methods metastatic or unresectable soft tissue bone sarcomas received 12.5 mg administered as a 30-minute intravenous infusion once daily for 5 days every 2 weeks....
Abstract BACKGROUND Angiosarcoma is a malignant tumor of vascular endothelial cells that arises in the head and neck. It rare, difficult to treat, lethal tumor. METHODS Clinical data from patients who were diagnosed with angiosarcoma scalp between 1975 2002 at University Michigan reviewed. Analysis was performed assess for factors impacting time recurrence survival. RESULTS The study comprised 29 median age 71.0 years. Most presented after delay diagnosis either bruise‐like macule (48.3%) or...
Purpose A recent report of the combination gemcitabine and docetaxel described favorable results in patients with uterine leiomyosarcoma. The objective this is to describe experience a variety histologic subtypes sarcoma. Additionally, cell-culture studies were performed assess effect sequence drug administration on colony formation. Patients Methods medical record review 35 receiving gemcitabine/docetaxel was undertaken. Gemcitabine 675 mg/m 2 intravenously administered over 90 minutes days...
Clinical Trials: Design, Conduct, and Analysis , by Dr Curtis Meinert, is a good reference for many practitioners of clinical trials. The book deals with single-center multiple-center randomized prospective trials, uses several examples (14) current important such as the University Group Diabetes Program, Persantine Aspirin Reinfarction Study, Hypertension Prevention Trial. In addition to necessary discussions on key ingredients study design, sample size power, randomization forms data...
Aggressive fibromatoses (AF; desmoid tumors) are rare clonal neoplastic proliferations of connective tissues that can be locally aggressive despite wide surgical resection and/or radiation therapy. The Sarcoma Alliance for Research through Collaboration (SARC) initiated a prospective phase II trial to investigate the outcome patients treated with imatinib, multiple tyrosine kinase inhibitor, in AF, or 1 10 sarcoma subtypes. Here, we report specifically on AF as well evaluations undertaken...
PURPOSE The purpose of this trial was to assess the efficacy imatinib in patients with one 10 different subtypes advanced sarcoma. PATIENTS AND METHODS Eligible were treated daily dosed at 300 mg twice a day (for body-surface area > or = 1.5 m(2)). primary end point response (clinical benefit [CBR]), defined as complete (CR) partial (PR) 2 months, stable disease, CR, PR 4 months. Rules for early termination within each disease type based on Bayesian hierarchical probability model (BHM)...
During the initial therapeutic evaluations of adriamycin and DIC, efficacy was noted with each in treatment advanced sarcomas. Preclinical studies suggested possible synergism without additive toxicity. This lead to our evaluating two agents combination metastatic Adriamycin at 60 mg/m2 given I.V. on day 1 DIC 250 days 5, entire regimen repeated every 21 days. The dosage both drugs reduced 25% patients extensive prior therapy. Of 120 entered, 100 were evaluable for efficacy. Five complete 36...